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Abstract
The management of patients with urinary tract stone disease has changed dramatically over recent
years, with current treatment modalities focused on their minimal invasiveness. In this article we will
discuss the recent advances in the field of urolithiasis management, with a focus on medical expulsive
therapy, extra-corporeal shockwave lithotripsy and ureteroscopy.
Introduction and context
Urinary tract stone disease is common; in Europe and in
the USA the lifetime risk of developing a stone is between
5 and 12%, more often affecting men than women. The
peak incidence is between the ages of 20 and 50 years.
Unfortunately, within 5 years of their first bout of renal
colic, 50% of patients will have stone recurrence. Not all
renal tract calculi need active intervention as distal
ureteric calculi of ≤5 mm in size have a spontaneous
passage rate of 71-98%.
Stone size and location are important when considering
conservative management, and analgesia is essential for
such patients, as the passage of a calculus is associated
with severe pain. Non-steroidal anti-inflammatory drugs
are commonly used for this, however, patients placed on
‘watchful waiting’ may benefit from adjuvant treatment
in the form of medical expulsive therapy (MET).
This article briefly reviews some of the current issues in
the management of ureteric calculi, including MET, extra-
corporeal shockwave lithotripsy and ureteroscopy. Some
of the latest developments, including the use of
isoproterenol and the application of robotics to flexible
ureterorenoscopy, are also discussed.
Recent advances
Medical expulsive therapy
In recent years there has been a growing trend in
administering medication (in addition to analgesia) to
patients with distal ureteric calculi in order to help with
expulsion of a calculus. There have been many trials
demonstrating the efficacy of such an approach, high-
lighted below.
Alpha adrenoceptor antagonists
Tamsulosin, alfuzocin and terazocin have all been used
in MET. The rationale behind the use of a1-antagonists
in MET has been that they are capable of decreasing the
resting tone of the ureter and interfering with ureteric
contractions, thereby decreasing the frequency of peri-
staltic contractions. Several studies have demonstrated
that alpha blockers expedite stone passage, decrease
pain, and hence, reduce analgesic requirements [1].
A recent study by Sigala et al. [2] looked at gene and
protein expression of alpha adrenoceptors in the
proximal, middle and distal ureters. They demonstrated
that a-1d mRNA was the most common overall (and is
expressed in all portions of the ureter), and that a-1
mRNA was found in greater abundance in the distal
ureter than more proximally.
Tamsulosin has been the most commonly studied alpha
blocker in MET and has equal affinity for a-1a and a-1d.
Cervenàkov et al. [3] were one of the first to carry out a
double blind randomised trial using tamsulosin. In their
series the rate of expulsion was 80.4% in the tamsulosin
group versus 62.8% with standard therapy without
tamsulosin. Since this study, the Italian authors
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in this field. Dellabella et al. [4] showed the effectiveness
of tamsulosin in improving overall stone expulsion rates
whilst reducing the patient’s analgesic requirements and
risk of readmission to hospital, particularly when
combined with a corticosteroid (which also reduced
the time to expulsion). More recently, Porpiglia et al.[ 5 ]
have reported the use of a second 10-day course of
tamsulosin for patients who had not yet passed their
stone after an initial treatment period of similar length.
In this study, a further 80% of patients successfully
passed a stone (compared with just under half of patients
who passed them spontaneously without additional
treatment). Figure 1 shows the effectiveness of alpha
blocker MET in seven randomized controlled trials for
distal ureteric stones.
Pedro et al. [6] performed a double blind randomised
trial using alfuzosin. The alfuzosin group demonstrated a
reduced time to distal stone expulsion and reduced
analgesic requirements but the rate of expulsion was not
increased. This may be an indication that alfuzosin is not
as effective as the other alpha blockers.
Calcium channel blockers
The use of calcium channel antagonists such as
nifedipine has also proved useful. Borghi et al. [7] carried
out a double blind randomised trial involving 86
patients who received methylprednisolone with either
placebo or nifedipine. The nifedipine cohort had a
significantly higher rate of stone passage at 87 versus
65%. Other studies comparing nifedipine against
tamsulosin seem to indicate that both drugs are useful,
but tamsulosin is more efficacious [1,6].
Corticosteroids
Steroids have also been used to aid stone passage. The
rationale for this treatmenti st h a ti tr e d u c e ss t o n e -
induced oedema and hence allows a calculus to pass.
Steroids combined with an alpha blocker proved more
efficacious than either a steroid or alpha blocker alone.
Porpiglia et al. [8] compared tamsulosin; deflazocort; a
combination of tamsulosin and deflazocort; and
analgesics (taken when required). The groups were
comparable in terms of age, sex, and stone size and
location. The rate of expulsion for the four groups was
60%, 37.5%, 84.8%, and 33.3%, respectively. Surpris-
ingly, deflazocort on its own was not very efficacious
compared to tamsulosin or combination therapy.
Patients benefit greatly from combination therapy
(84.8% expulsion rate) but if steroids are contra-
indicated (that is, because of diabetes or history of
peptic ulceration) then adjuvant alpha blocker therapy
will be of benefit (60% expulsion rate).
MET has been shown to be cost-effective by reducing
the number of ureteroscopic procedures that would be
required following observation alone. Provided that
ureteroscopy is not extremely cheap and MET is not very
expensive, or spontaneous stone passage rates are not
extremely high (and therefore need neither MET nor
ureteroscopy) or extremely low (and therefore require a
ureteroscopy whether treated by MET or not), MET is
a cost-effective treatment. In the USA, this approach
would result in a theoretical $1,132 cost saving per
patient over observation, a saving that is related to the
very high cost of ureteroscopy in the USA and the
relatively low cost of tamsulosin. In fact, due to the cost
differences between the two treatments, if only one
ureteroscopy per 100 treated patients is avoided
because of MET, then it would still be a cost effective
treatment in the USA [9].
Extra-corporeal shockwave lithotripsy
Extra-corporeal shockwave lithotripsy has been used for
many years and is an effective treatment modality for a
select group of patients. It has been shown to be very
efficacious for upper ureteric stones of ≤10 mm in size.
Multiple large series have shown stone-free rates of over
80% for proximal ureteric calculi. In a series of 397
patients with an upper ureteric stone, 91% had a calculus
diameter of ≤14 mm and this cohort had an 84.3%
stone-free rate at 3 months. However, with increasing
Figure 1. Effectiveness of MET with alpha-blocker drugs for distal
ureteral stones
The graph shows that spontaneous passage rates vary from 43-73%. These
increase from 76-100% with the addition of MET using an alpha-blocker
drug, and these improvements are generally statistically significant.
aP-value
not available;
bP = 0.001;
cP = 0.196;
dP = 0.01;
ethe expulsion rate shown
here is the mean rate recorded in this study between tamsulosin (79.31%,
P = 0.03), terazosin (78.57%, P = 0.03) and doxazosin (75.86%, P = 0.04);
fP < 0.001;
gP = < 0.000. Taken together, the meta-analysis by Hollingsworth
et al. [16] demonstrated that patients given medical therapy (with either a
calcium channel antagonist or alpha-blocker) had a 65% greater likelihood of
stone passage without intervention. MET, medical expulsive therapy.
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Compact Delta lithotripter the success rate at 3 months
was reported as 96% for calculi ≤10 mm and 90% for
those 11-20 mm in diameter [10].
Ureteroscopy
Along with ongoing develop m e n to fs a f e t y / w o r k i n g
wires and basket design and size, one of the key
advances in ureteroscopy relates to the improved image
quality itself, with the development of digital uretero-
scopes with ‘chip in the tip’ technology. Such systems
can be illuminated by LEDs (light-emitting diodes) in
the tip of the scope, and an external light source may
not therefore be required. In addition to the remark-
able improvement in image quality, such scopes are
lighter (there is no need for an external camera to be
attached), inherently safer (there is no risk of drape or
patient burns from the external light source), and
possibly more durable (there are no fragile fibre-optics
within the scope since the image is transmitted
digitally) [11,12].
It has been suggested that the considerable improvement
in image quality over conventional analogue scopes may
allow the earliest stages of stone formation to be better
appreciated,andhenceimproveourunderstandingofthe
pathogenesis of calcium oxalate stone formation [13].
Isoproterenol and ureteroscopy
Through its effect on relaxation of ureteric tone, the use
of endoluminal isoproterenol in the irrigation fluid has
been shown to reduce pelvic pressure compared with
saline irrigation without affecting heart rate or mean
arterial blood pressure. Significant increases in intra-
renal pressure do occur during ureteroscopy (especially
during injection of contrast) and these may be associated
with complications, including urinary sepsis due to
pyelovenous and pyelolymphatic reflux. The reduction
of intra-pelvic pressure, without associated cardiovascu-
lar side effects, therefore offers a potentially useful safety
step in ureteroscopy [14].
Robotics
Whilst not reported for the treatment of ureteric calculi as
yet, the extension of robotics to ureteroscopy deserves a
mention. Desai and colleagues [15] have recently
described the use of a modified robotic catheter system
for ureterorenoscopy that had been originally developed
for intra-cardiac applications.
In this feasibility study using a pig model, they were able
to inspect 98% of calyces using a steerable guide catheter
controlled remotely via a three-dimensional joystick.
They reported that the robotic method was ‘stable,
easily manoeuvrable, and ergonomically superior’ to
conventional ureterorenoscopy. Intra-renal therapeutic
manoeuvres were also possible, including the complete
fragmentation of small stones. They found that the
combination of the precise positioning of the catheter tip
and its subsequent stability allowed the system to be
‘parked’ in a calyx for prolonged periods, improving the
ability to target small fragments for further fragmenta-
tion. However, they identified significant extravasation
of irrigation fluid following these procedures, and have
subsequently reduced the size of the prototype ureteror-
enoscope to 7.5 F [15].
Implications for clinical practice
Although already in widespread use, and supported by
the 65% relative increased chance of stone passage
compared with non-treatment, MET still requires a well-
designed randomized trial to confirm its effectiveness
and best practice in the management of ureteric stones.
Until then, MET is useful in patients who do not require
more urgent intervention, but its ‘off-label’ use should be
emphasized.
The ability to treat large, proximal ureteric stones, with a
good chance of being stone-free in one procedure,
continues to be the goal of ureteroscopic stone manage-
ment. The use of isoproterenol, the first report of
pharmacological manipulation of the ureter intra-opera-
tively [14], could potentially reduce the risk of septic
complications following ureteroscopy; if so, then it may
not be long before this strategy is taken up by others,
and, if proven to be effective in randomized trials in
humans, could become as standard a step in uretero-
scopy as the insertion of a safety wire.
Using their robotic system, Desai et al. [15] were able to
decrease the time required for a complete examination of
the kidney down to under a minute; however, the
learning curve for this is likely to be greater for those
without as much robotic or ureterorenoscopic experi-
ence. Further improvements to the method, and details
of its use in a clinical setting, will no doubt reach the
literature soon, and evidence of wider dissemination of
this technique is pending. Inevitably, the cost implica-
tions of establishing a robotic ureterorenoscopic pro-
gramme, relative to the ability of experienced operators
to gain access to each calyx, and similarly to ‘park’ the tip
of a conventional flexible ureterorenoscope in the
desired calyx for sufficient time to completely treat the
stone within, remains to be quantified and will play a
significant role in wider acceptance.
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MET, medical expulsive therapy.
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